Annji Pharmaceutical Co. Ltd. (中国台湾地区)

The Company is a Taiwan-based company mainly focuses on innovative new drug projects with high chances of success,
concentrates resources on the development of three main axes, including nuclear factor E2-related factor 2 (Nrf2) activator (AJ201), highly selective histone deacetylase 6 (HDAC6) inhibitor (AJ302), and next-generation androgen degradation promoter (AJ202). AJ201 oral suspension is used to treat neurodegenerative diseases caused by polyglutamine (polyQ), among which spinal and bulbar muscular atrophy (SBMA) is the first disease to be verified by clinical concept. AJ302 sustained-release injection is used to treat peripheral neuritis caused by chemotherapy. AJ202 scalp topical is used to treat male pattern baldness. Its products are mainly sold to European and American markets.
History
The Company was established on December 15, 2014.The Company listed on Public Companies of Taiwan Stock Exchange on June 17, 2024.The Company listed on Emerging Stocks of Taiwan Stock Exchange on June 25, 2024.